News | EP Lab | December 08, 2015

Biotronik Begins Study of Closed Loop Stimulation for Atrial Fibrillation Patients

Randomized, controlled B3 trial will determine if CLS can delay onset of clinically relevant AF and reduce stroke risk

Biotronik, CLS, B3 clinical trial, atrial fibrillation, AF patients, stroke risk

December 8, 2015 — Biotronik announced the first patient enrollments to the B3 clinical trial. The study will evaluate the potential clinical benefit of the physiologic rate response sensor Closed Loop Stimulation (CLS) in atrial fibrillation (AF) patients. It will assess whether pacemakers and implantable cardioverter-defibrillators (ICDs) with CLS can reduce the rate of stroke and improve patient outcomes.

AF is one of the most common cardiac arrhythmias; a significant risk factor for stroke, it is estimated to cause approximately 15 percent of all ischemic strokes and as many as 30 percent of strokes for patients in their eighties.

“AF is a huge clinical challenge, affecting over 20 million patients in Europe and the U.S. alone,” commented first implanter and international coordinator for the study  Valeria Calvi, M.D., University of Catania, Ferrarotto Hospital, Italy. “I am very excited to begin this groundbreaking trial. We hope to demonstrate that the physiological heart rate modulation induced by CLS in sick sinus disease patients can control clinically relevant AF episodes. CLS may well improve clinical outcomes and lower the incidence of stroke in this particularly challenging patient population.”

The large multicenter trial will include 52 study centers in Italy, Spain, China, Taiwan, Korea, Singapore, Malaysia and India. Investigators will randomize 1,308 patients with a pacemaker or ICD indication who require dual-chamber pacing due to sinus node disorder (SND) into two groups. Patients in each study arm are to receive a Biotronik pacemaker or ICD with CLS turned either on or off. The trial’s primary endpoint is the time to first onset of new clinically relevant AF episodes or thromboembolic events, and there will be a follow-up period of three years. As a secondary endpoint, the study will investigate whether a subgroup of patients remotely monitored using Biotronik Home Monitoring is associated with an even further reduced risk of stroke and persistent AF.

CLS rate adaptive technology has been available in select pacemakers for two decades, and more recently in ICDs and CRT devices. CLS integrates into the natural cardiovascular control system and determines the appropriate heart rate based on intracardiac impedance measurements. These measurements reflect changes of the cardiac contraction dynamics in reaction to information coming from the autonomic nervous system. In doing so, CLS provides optimal heart rates under varied circumstances, even during acute mental stress.

For more information: www.biotronik.com

Related Content

Frequent Drinking Greater Risk Factor for Heart Rhythm Disorder Than Binge Drinking

Image courtesy of the American Heart Association.

News | Atrial Fibrillation | October 22, 2019
October 22, 2019 —  Drinking small amounts of alcohol frequently is linked with a higher likelihood of...
Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Feature | Atrial Fibrillation | July 24, 2019
July 24, 2019 — Atrial fibrillation (AFib) is a common abnormal heart rhythm.
New Technology Improves Atrial Fibrillation Detection After Stroke
News | Atrial Fibrillation | July 19, 2019
A new method of evaluating irregular heartbeats outperformed the approach that’s currently used widely in stroke units...
An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures.

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures. 

News | Atrial Fibrillation | May 14, 2019 | Dave Fornell, Editor
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vei
The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial.

The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial. 

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce...
More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A digital screening for...
Overlay Init